Mangoceuticals Inc MGRX

$0.44 -0.04 (-9.03%)

Valuation

Market cap
10,363,000
Revenue TTM
$460,000
Net income TTM
$-20,640,000
PE ratio
0.00
Forward PE
—
Profit margin
-4,486.96%
Debt to equity
0.00

Trading

Volume
877,200
Avg volume
16,239,388
Day's range
$0.43 – $0.44
Shares out
21,567,000
Stochastic %K
45%
Beta
1.98
Analysts
Strong Buy
Price target
—

Price

Company profile

Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testoste...

Show more

Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. In addition, the company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.

Industry
Health Information Services
Sector
Healthcare
Phone
214 242 9619
Website
https://www.mangoceuticals.com
Address
17130 N. Dallas Parkway, Suite 240, Dallas, United States

Latest news

Stocktwits

bundy3333 Oct 2, 1:42 PM
$MGRX According to Mangoceuticals’ annual SEC filings, the company closed 2025 with 15,487,487 common shares outstanding and a total stockholders' equity of $3,281,495 [MGRX 10-K Dec 31 2025]. However, during the first half of 2026, the company ballooning the share count to 29,548,726 shares by June 30, 2026 [MGRX 10-Q June 30 2026]. Assuming no further shares are issued in H2 2026 the evaluation of Book Value per Share (BVPS) Year-End 2026 with shareholders' equity of $ 5,537,482 projected Your true intrinsic book value per share drops from $0.21 to $0.19 (an 11.4% destruction in per-share value). This BVPS proves why the market is currently pricing the stock not at least for 10 Trading sessions in a row above the minimum required $ 1 for NASDAQ compliant listing. The stock trades at a premium around 100 to 150 % to its tangible book value because investors are waiting to see if the company can actually commercialize the remaining 75% of the patent asset before the cash runs dry again.
1 replies
stockobserver Oct 1, 8:25 PM
$MGRX Turd
0 replies
FredFeuerstein Oct 1, 8:03 PM
$MGRX for about 2seconds
0 replies
FredFeuerstein Oct 1, 7:59 PM
$MGRX WHAT??
0 replies
winners234 Oct 1, 7:56 PM
$MGRX https://app.trendvision.bot/n/6abeb9689fe1c10001da2234
0 replies
RAIK7 Oct 1, 7:54 PM
$MGRX https://www.stocktitan.net/news/MGRX/mangoceuticals-secures-2-5-million-strategic-investment-in-mango-rx-isaz2mfmu8ej.html
0 replies
i_like_bb_stock Oct 1, 7:54 PM
$MGRX < $.50C - Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche
0 replies
fivehundredpercent Oct 1, 7:53 PM
$MGRX I think it's close to breakout .50 was big level
0 replies